Europe’s leading cancer conference may be swimming in antibody-drug conjugate (ADC) data, but AstraZeneca remains convinced ...

Roche’s giredestrant was shown to reduce the risk of breast cancer progression or death by 62% for a specific cohort of a ...

Xoma Royalty and Lava Therapeutics are turning the temperature down, dropping both the cash per share offer and closing cash ...

A pair of antibody-based biotech deals emerged late this week, encompassing separate licensing pacts from China’s Hansoh ...

Danish vaccine developer Evaxion has released long-term data for its lead personalized cancer vaccine, with the shot scoring ...

The Big Pharma’s window to take up exclusive rights to Taysha’s lead asset, dubbed TSHA-102, has officially closed, according ...

The FDA has handed out the first nine national priority vouchers, positioning companies including Merck KGaA, Regeneron and ...

A year ago, Pfizer tied a subcutaneous injection of the highest dose of the anti-GDF-15 antibody ponsegromab once every four ...

T, this time inking a deal worth up to $1.64 billion biobucks with Chinese biotech Pregene Biopharma. | Gilead’s Kite Pharma ...

Consumers are eager to use a range of medical devices at home, but are wary of AI in these technologies and want accurate ...

President Donald Trump has telegraphed a new round of 100% tariffs on all Chinese imports beginning in November. The U.S. has ...

Praxis Precision Medicines’ commitment to forging ahead with ulixacaltamide in essential tremor (ET) has paid off. | The ...